How much does Sucralfate cost?

Pricing for Sucralfate varies by insurance plan, dose, and pharmacy. Our database does not show a fixed cost because prices change faster than we can verify. For current pharmacy prices, check your insurance's formulary tier (in the prior-authorization section), use the GoodRx or Cost Plus Drugs deep links on this page, or ask your pharmacist to run a test claim. If a copay card is listed, it usually drops the out-of-pocket significantly for commercial insurance.

Does Sucralfate need prior authorization?

Sucralfate appears on 3 payer formularies in our database. PA requirements vary by payer — see the prior-authorization table on this page for specifics. In general, specialty and brand-name drugs are more likely to require PA than generic equivalents.

Is there a copay card or patient assistance program for Sucralfate?

We haven't verified an active copay card or PAP for Sucralfate in our current data. Check NeedyMeds or RxAssist for independent directories, or submit what you find via our "Report a broken link" form.

What is Sucralfate used to treat?

Sucralfate (generic: Sucralfate) is indicated for Peptic Ulcer State, Duodenal Ulcer, Peptic Ulcer. Click any condition name on this page for more detail.

Sucralfate

Generic: Sucralfate

Verified·Apr 23, 2026

Manufacturer: Allergan
NDC: 82182-106
RxCUI: 314234
Route: ORAL
ICD-10 indication: K26.9

Affordability Check

How much will you actually pay for Sucralfate?

In 30 seconds, see every legitimate way to afford Sucralfate — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.

Check my options →

About Sucralfate

What is this medication?

Sucralfate is a prescription medication primarily used to treat and prevent ulcers in the intestines, specifically duodenal ulcers. Unlike other medications that work by reducing stomach acid, sucralfate acts as a physical barrier. When it enters the digestive system, it reacts with the acid in the stomach to create a thick, paste-like substance. This substance adheres directly to the damaged ulcer tissue, acting like a protective bandage that shields the area from stomach acid, enzymes, and bile salts. This allows the ulcer to heal more effectively by preventing further irritation from the harsh environment of the digestive tract.

In addition to treating active ulcers, healthcare providers may prescribe sucralfate for short-term maintenance therapy to prevent an ulcer from returning after it has healed. It is often taken multiple times a day on an empty stomach to ensure it can coat the stomach lining properly. While its primary role is for duodenal ulcers, it is sometimes used for other conditions like gastroesophageal reflux disease or mouth sores caused by certain medical treatments. Because it stays mostly within the digestive tract and is not absorbed significantly into the bloodstream, it generally has fewer systemic side effects compared to other medications, though it can interfere with the absorption of other drugs.

Copay & patient assistance

Detailed copay and financial assistance information is not publicly available for this medication at this time. Please consult your pharmacist or the manufacturer's official patient support program for more details.

External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.

Compare pricing elsewhere

RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.

Cost Plus Drug Company

Mark Cuban's transparent-pricing pharmacy — manufacturer cost + 15% markup + $5 dispensing fee. No insurance needed. Search alphabetically for Sucralfate.

Browse Cost Plus medications →

GoodRx

Compare local pharmacy prices with GoodRx coupons. Use the price with your insurance or without — whichever is cheaper.

Lookup Sucralfate →

NeedyMeds

Independent nonprofit directory of patient assistance programs, copay cards, and charity co-pay foundations.

Search for Sucralfate →

RxAssist

PAP directory maintained by Volunteers in Health Care at Brown University. Free, no ads.

Search PAPs →

We deep-link because transparency helps patients. None of these partners pay RxCopays.

Prescribing information

From the FDA-approved label for Sucralfate. Official source: DailyMed (NLM) · Label effective Feb 10, 2024

Indications and usage

INDICATIONS AND USAGE Sucralfate Oral Suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer.

Dosage and administration

DOSAGE AND ADMINISTRATION Acti v e Duodenal Ulcer : The recommended adult oral dosage for duodenal ulcer is 1 gram (10 mL) four times per day. Sucralfate Oral Suspension should be administered on an empty stomach. Antacids may be prescribed as needed for relief of pain but should not be taken within one-half hour before or after Sucralfate Oral Suspension. While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. Elderly : In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (See PRECAUTIONS, Geriatric Use ). Call your doctor for medical advice about side effects.You may report side effects to AbbVie, Inc. at 1-800-678-1605 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

Contraindications

CONTRAINDICATIONS Sucralfate Oral Suspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients.

Warnings

WARNINGS Fatal complications, including pulmonary and cerebral emboli have occurred with inappropriate intravenous administration of Sucralfate Oral Suspension. Administer Sucralfate Oral Suspension only by the oral route. Do not administer intravenously.

Drug interactions

Drug Interactions Some studies have shown that simultaneous sucralfate administration in healthy volunteers reduced the extent of absorption (bioavailability) of single doses of the following: cimetidine, digoxin, fluoroquinolone antibiotics, ketoconazole, l-thyroxine, phenytoin, quinidine, ranitidine, tetracycline, and theophylline. Subtherapeutic prothrombin times with concomitant warfarin and sucralfate therapy have been reported in spontaneous and published case reports. However, two clinical studies have demonstrated no change in either serum warfarin concentration or prothrombin time with the addition of sucralfate to chronic warfarin therapy. The mechanism of these interactions appears to be nonsystemic in nature, presumably resulting from sucralfate binding to the concomitant agent in the gastrointestinal tract. In all cases studied to date (cimetidine, ciprofloxacin, digoxin, norfloxacin, ofloxacin, and ranitidine), dosing the concomitant medication 2 hours before sucralfate eliminated the interaction. Due to Sucralfate Oral Suspension’s potential to alter the absorption of some drugs, Sucralfate Oral Suspension should be administered separately from other drugs when alterations in bioavailability are felt to be critical. In these cases, patients should be monitored appropriately.

Adverse reactions

ADVERSE REACTIONS Adverse reactions to sucralfate tablets in clinical trials were minor and only rarely led to discontinuation of the drug. In studies involving over 2700 patients treated with sucralfate, adverse effects were reported in 129 (4.7%). Constipation was the most frequent complaint (2%). Other adverse effects reported in less than 0.5% of the patients are listed below by body system: Gastrointestinal: diarrhea, dry mouth, flatulence, gastric discomfort, indigestion, nausea, vomiting Derm a tolog i cal: pruritus, rash Ner v ous S y s tem: dizziness, insomnia, sleepiness, vertigo Oth e r: back pain, headache Post- ma rk e ting cases of hypersensitivity have been reported with the use of sucralfate oral suspension, including anaphylactic reactions, dyspnea, lip swelling, edema of the mouth, pharyngeal edema, pruritus, rash, swelling of the face and urticaria. Cases of bronchospasm, laryngeal edema and respiratory tract edema have been reported with an unknown oral formulation of sucralfate. Cases of hyperglycemia have been reported with sucralfate. Bezoars have been reported in patients treated with sucralfate. The majority of patients had underlying medical conditions that may predispose to bezoar formation (such as delayed gastric emptying) or were receiving concomitant enteral tube feedings.

Use in pregnancy

Pregnancy Teratogenic effects Teratogenicity studies have been performed in mice, rats, and rabbits at doses up to 50 times the human dose and have revealed no evidence of harm to the fetus due to sucralfate. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Label text is reproduced as-is from the FDA-approved label. We do not paraphrase, summarize, or omit. Content above is for informational purposes only and is not medical advice. Always consult your prescribing clinician or pharmacist before making decisions about your medication.

Conditions we've indexed resources for

Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.

Medicare Part D coverage

How Sucralfate appears across Medicare Part D plan formularies nationally. Source: CMS monthly Prescription Drug Plan file (2026-04-30).

Covered by plans

71%

3,895 of 5,509 plans

Most common tier

Tier 2

On 57% of covering formularies

Prior authorization required

of covering formularies

Tier	Formularies on this tier	Share
Tier 1 (preferred generic)	102	31%
Tier 2 (generic)	188	57%
Tier 3 (preferred brand)	37	11%
Tier 4 (non-preferred brand)	2	1%

Step therapy: 0% of formularies

Quantity limits: 0% of formularies

Coverage breadth: 329 of 65 formularies

How to read this:plans on the same formulary share tier + PA rules. Your specific plan's copay depends on (a) the tier above, (b) your plan's cost-share for that tier, (c) whether you're in the initial coverage phase or past the 2026 $2,000 out-of-pocket cap. For your exact plan, check its Summary of Benefits or log in to your Medicare.gov account. Copay cards don't apply to Medicare (federal law).

Prior authorization & coverage

Payer	PA	Step therapy	Copay tier
— Medicare Part D	—	—	—
— Medicare Part D	—	—	—
— Medicare Part D	—	—	—

Payer

Step therapy

Copay tier

—

Medicare Part D

—

Medicare Part D

—

Medicare Part D

—

Related drugs

How this page is sourced

Drug identity verified against openFDA NDC Directory.
Label text (when shown) originates from NLM DailyMed.
Copay and assistance URLs verified periodically; if you hit a broken link, tell us.